Close this search box.

The Institute for Clinical and Economic Review has issued a draft report concluding that targeted immune modulators, such as biologic treatments, for rheumatoid arthritis are too expensive. The conclusion could embolden health plans to limit patient access.

But does ICER’s model accurately reflect the experiences of the 1.5 million Americans with rheumatoid arthritis?

View the Graphic

Leave a Reply

Your email address will not be published. Required fields are marked *